Please login to the form below

Not currently logged in
Email:
Password:

ZS Pharma

This page shows the latest ZS Pharma news and features for those working in and with pharma, biotech and healthcare.

FDA turns down AZ's ZS-9 once again on manufacturing issues

FDA turns down AZ's ZS-9 once again on manufacturing issues

AZ and ZS Pharma are committed to working with the FDA to resolve the remaining matters under review as soon as possible," it said in a statement. ... When AZ bought ZS Pharma it described ZS-9 as a "best in class" potassium-binder with sales potential

Latest news

  • AZ nears EU approval for hyperkalaemia drug Lokelma AZ nears EU approval for hyperkalaemia drug Lokelma

    The drug was originally developed by ZS Pharma, which described Lokelma as a “ potential best-in-class treatment” and tipped it as a potential blockbuster. ... Speaking at the time of ZS Pharma's acquisition, AstraZeneca's chief executive Pascal

  • AZ slims down again with sale of antibiotics to Pfizer AZ slims down again with sale of antibiotics to Pfizer

    In May the big pharma company was estimated to be sitting on around $40bn - giving it plenty of scope to for pipeline-bolstering deals. ... Meanwhile, recent pipeline-boosting acquisitions have included a $2.7bn purchase of ZS Pharma, a majority stake in

  • Actelion claims first approval for PAH therapy Uptravi Actelion claims first approval for PAH therapy Uptravi

    It was also in discussions about a merger with ZS Pharma, before the latter opted instead for a $2.7bn takeover by AstraZeneca (AZ).

  • AZ takes majority stake in cancer drug developer Acerta AZ takes majority stake in cancer drug developer Acerta

    AstraZeneca's negotiations with Acerta Pharma BV have been successfully concluded, with AZ agreeing to take a 55% stake in the Dutch biopharma company for $4bn. ... Last month, it added to its cardiovascular portfolio with a $2.7bn deal to buy ZS Pharma

  • AstraZeneca sets sights on China with Takeda deal AstraZeneca sets sights on China with Takeda deal

    The UK-based pharma major already has rights to Daliresp in the US. ... The two deals come amid a flurry of M&A activity at AZ, which confirmed it is in negotiations to buy Acerta Pharma earlier this week and snapped up ZS Pharma

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    The CRL refers to a manufacturing issue. ZS-9 was acquired when the company purchased ZS Pharma for $2.7bn. ... Reported in DW Issue 65 [November 2015] AstraZeneca had out bid Actelion who were also in the running to buy ZS Pharma at that time.

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    metabolism. Meanwhile, further evidence for an uptick in pharma industry interest in HF is witnessed by recent licensing/acquisition deals. ... of ZS Pharma and ZS-9, a drug being developed to treat elevated potassium levels in HF patients.

  • Deal Watch November 2015 Deal Watch November 2015

    Also doing the double and buying and selling AstraZeneca continued its busy deal profile with the acquisition of ZS Pharma and the divestment in the US of Entocort. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9, potassium-binding

  • Pharma deals in September 2015 Pharma deals in September 2015

    Transformational deals. The two largest deals announced this month were Cinven's sale of Amdipharm Mercury (AMCo) to Concordia Healthcare and Actelion's move to acquire ZS Pharma, at $3.5bn ... 3, 500. ZS Pharma. Actelion. ZS-9 to treat hyperkalemia

  • Sales reps struggle to access doctors Sales reps struggle to access doctors

    Relationships reached by sales force size. Source: ZS Associates. Making proper use of that well-worn buzz word 'customer-centric' marketing will be key - along with careful channel choice – if pharma ... companies are to gain physician attention, but

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics